omocianine

Omocianine is a small molecule near-infrared (NIR) fluorescent dye developed by Bayer Schering Pharma (formerly Schering AG) for use as a diagnostic contrast agent. It was primarily investigated for the detection of breast cancer using diffuse optical tomography (DOT), a non-invasive imaging technique. The compound is designed to accumulate in tumor tissues or highlight vascular changes associated with malignancy, allowing for improved optical visualization. Clinical trials evaluated its safety and efficacy via intravenous administration, where it demonstrated a good safety profile with no reported adverse events.